

BVG Life Sciences Limited

Financial statements together with the
Independent Auditors' Report for the year
ended 31 March 2019

BVG Life Sciences Limited

**Financial statements together with the Independent Auditors' Report
for the year ended 31 March 2019**

Contents

Independent Auditors' Report

Balance Sheet

Statement of Profit and Loss

Cash Flow Statement

Notes to the financial statements

ANRK & Associates LLP

Chartered Accountants

2nd Floor, Shreeram Apartments
1244-B, Apte Road
Deccan Gymkhana
Pune-411 004

Telephone: +91(20) 25530144

Independent auditor's report

**To the Members of
BVG Life Sciences Limited
Report on the audit of the Financial Statements**

Opinion

We have audited the accompanying financial statements of BVG Life Science Limited ("the Company") which comprise the Balance Sheet as at 31 March 2019, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2019, profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Other information

The Company's Management and Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



BVG Life Sciences Limited
Independent Auditor's Report (continued)

Management's responsibility for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. The Company does not meet the revenue and aggregate criteria for borrowings during the year. Accordingly, the report on the Internal Financial Controls under clause (i) of sub section 3 of section 143 of the Act is not applicable to the Company.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



BVG Life Sciences Limited
Independent Auditor's Report (continued)


- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government in terms of section 143 (11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. A) As required by section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with Accounting Standards specified under Section 133 of the Act.
 - e) On the basis of the written representations received from the directors as on 31 March 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) Since the Company's turnover as per last audited financial statements is less than 50 crores and its borrowings from banks and financial institutions at any time during the year is less than 25 crores, the Company is exempted from getting an audit opinion with respect to the adequacy of



BVG Life Sciences Limited
Independent Auditor's Report (continued)

the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls vide notification dated June 13, 2017.

- B) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i) The Company did not have any pending litigations impacting its financial position.
 - ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv) The disclosures regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made in these financial statements since they do not pertain to the financial year ended 31 March 2019.
- C) The provisions of section 197 read with Schedule V to the Act have been complied with by the Company.

For ANRK & Associates LLP
Chartered Accountants
Firm Registration Number: W-100001



Abhijit Jadhav
Partner
Membership Number: 135735
Place: Pune
Date: 30 September 2019
UDIN: 19135735AAAAKU2913.



BVG Life Sciences Limited
Annexure A to Independent Auditors' Report

Referred to the 'Annexure A' in paragraph 1 in Report on Other Legal and Regulatory Requirements of the Independent Auditors' Report to the members of BVG Life Sciences Limited ("the Company") on the financial statements for the year ended 31 March 2019, we report that:

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets, in manner so required.
- (b) The Company has a regular program of physical verification of its fixed assets, by which all fixed assets are verified at the end of each year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. According to the information and explanation given to us, the Company has physically verified fixed assets during the year in accordance with the program. No material discrepancies were noticed on such verification.
- (c) The title deeds of immovable properties are held in the name of Company as on the date of balance sheet.
- (ii) The inventory has been physically verified at reasonable intervals by the management during the year. In our opinion, the frequency of such verification is reasonable and adequate in relation to the size of the Company and nature of its business. The discrepancies noticed on verification between the physical stocks and the book records were not material and have been properly dealt with in the books of account.
- (iii) According to the information and explanation given to us, the Company has not granted any loans secured or unsecured to any companies, firms or parties covered in the register maintained under section 189 of the Act.
- (iv) In our opinion and according to the information and explanations given to us, the Company has not given any loan, guarantee or security to persons covered under section 185 nor given any security covered under section 186 of the Act.
- (v) The Company has not accepted any deposits in accordance with the provisions of section 73 to 76 of the Act and rules made there under.
- (vi) The provisions of section 148(1) of the Act for maintenance of cost records are not applicable to the Company.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Income Tax, Goods and Service Tax, Employee's State Insurance and other material statutory dues have been regularly deposited by the Company with the appropriate authorities *except for delay of days in case of Tax deducted at Source payments ranging from 8 to 65 days*. As explained to us, the Company did not have any dues on account of Excise Duty and Duty of Customs.


According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Income Tax, Employee's State Insurance, Goods and Service Tax and other material statutory dues were in arrears as at 31 March 2019 for a period of more than six months from the date they became payable.



BVG Life Sciences Limited
Annexure A to Independent Auditors' Report (continued)

- (b) According to the information and explanations given to us, there are no dues of Income tax, Sales tax, Service tax, Value Added Tax, Goods and Service Tax which have not been deposited on account of any dispute.
- (viii) The Company did not have any dues to financial institutions, government or any debentures outstanding during the year.
- (ix) In our opinion and according to the information and explanations given to us, the Company had not raised money by way of term loans, initial public offer or further public offer (including debt instruments) during the year.
- (x) According to the information and explanations given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- (xi) The provisions of section 197 read with Schedule V to the Act are not applicable to the Company. Accordingly, the provisions of clause 3 (xi) of the Order are not applicable to the Company.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company as per the Act.
- (xiii) In our opinion and according to the information and explanations given to us, all the transactions with related parties are in compliance with 188 of the Act and the details, as required by the applicable accounting standards, have been disclosed in the financial statements. The provisions of Section 177 are not applicable to the Company and accordingly reporting under clause 3(xiii) in so far as it relates to Section 177 of the Act is not applicable to the Company.
- (xiv) The Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of Clause 3(xiv) of the Order are not applicable to the Company.
- (xv) According to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with them during the year.
- (xvi) In our opinion, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company.

For ANRK and Associates LLP
Chartered Accountants
Firm Registration Number: W-100001



Abhijit Jadhav
Partner
Membership Number: 135735
Place: Pune
Date: 30 September 2019
UDIN: 19135735AAAAKU2913



BVG Life Sciences Limited

Balance Sheet

as at 31 March 2019

	Note	31 March 2019	31 March 2018
Equity and Liabilities			
Shareholders' funds			
Share capital	3	500,000	500,000
Reserves and surplus	4	9,792,176	900,282
		<u>10,292,176</u>	<u>1,400,282</u>
Non-current liabilities			
Long term borrowing	5	201,015,106	118,409,361
		<u>201,015,106</u>	<u>118,409,361</u>
Current liabilities			
Trade payables	6	37,323,880	8,625,007
Other current liabilities	7	12,890,018	6,339,412
		<u>50,213,898</u>	<u>14,964,419</u>
Total		<u><u>261,521,180</u></u>	<u><u>134,774,062</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible fixed assets	8(a)	15,294,242	1,279,877
Intangible assets	8(b)	588,425	342,892
Capital work-in-progress	8(c)	90,996,029	53,339,472
Long-term loans and advances	9	9,070,869	8,193,062
		<u>115,949,565</u>	<u>63,155,303</u>
Current assets			
Inventories	10	30,139,034	7,732,883
Trade receivables	11	70,694,287	21,981,347
Cash and bank balances	12	2,457,314	3,922,536
Short-term loans and advances	13	42,280,980	37,981,993
		<u>145,571,615</u>	<u>71,618,759</u>
Total		<u><u>261,521,180</u></u>	<u><u>134,774,062</u></u>

For ANRK & Associates LLP
Chartered Accountants
Firm Registration Number: W-100001



Abhijit Jadhav
Partner

Membership Number: 135735

Place: Pune

Date: 30 September 2019

UDIN: 19135735AAAAKU2913



For and on behalf of the Board of Directors of
BVG Life Sciences Limited




Hanmantrao Gaikwad
Director

DIN: 01597365

Place: Pune

Date: 30 September 2019



Umesh Mane
Director

DIN: 01597742

Place: Pune

Date: 30 September 2019

BVG Life Sciences Limited

Statement of Profit and Loss for the year ended 31 March 2019

	Note	31 March 2019	31 March 2018
Income			
Revenue from operations	14	192,802,438	56,589,435
Other income	15	2,268,059	12,069
Total revenue		195,070,497	56,601,504
Expenses			
Cost of material consumed	16	15,797,271	7,193,810
Purchase of traded goods	17	113,464,368	14,405,122
(Increase)/decrease in inventory of traded goods	18	(19,124,186)	16,533,557
Employee benefits	19	30,164,318	3,326,580
Other expenses	20	45,250,269	13,208,325
Depreciation	8(a),(b)	626,563	275,370
Total expenses		186,178,603	54,942,764
Profit before tax		8,891,894	1,658,740
Tax expense			
Current year		1,710,800	312,137
MAT credit entitlement for current year		(1,710,800)	(312,137)
Profit after tax		8,891,894	1,658,740
Basic and diluted loss per equity share of Rs. 10 each (in Rupees)		177.84	33.17

For ANRK & Associates LLP
Chartered Accountants
Firm Registration Number: W-100001



Abhijit Jadhav
Partner
Membership Number: 135735
Place: Pune
Date: 30 September 2019
UDIN: 19135735AAAaku2913



For and on behalf of the Board of Directors of
BVG Life Sciences Limited



Hanmantrao Gaikwad
Director
DIN: 01597365
Place: Pune
Date: 30 September 2019



Umesh Mane
Director
DIN: 01597742
Place: Pune
Date: 30 September 2019



BVG Life Sciences Limited

Cash flow Statement for the year ended 31 March 2019

	31 March 2019	31 March 2018
A Cash flow from operating activities		
Net loss before tax	88,91,894	16,58,740
Adjustment to reconcile (loss) before tax to net cash flows:		
Depreciation	6,26,563	2,75,370
Unrealised foreign exchange loss	-	52,055
Sundry balances written back	-	(2,094)
Operating loss before working capital changes	95,18,457	19,84,071
Movements in working capital:		
Decrease / (increase) in inventories	(2,24,06,151)	1,95,90,871
(Increase) in trade receivables	(4,87,12,940)	(1,53,12,745)
Decrease in short term loans and advances	(42,98,988)	5,76,202
(Increase) in long term loans and advances	(8,77,807)	(3,20,925)
(Decrease) in trade payables	2,86,98,873	(1,66,476)
Increase in other current liabilities	65,50,606	44,10,765
	(4,10,46,406)	87,77,692
Cash used in operations		
Income tax paid	-	-
Net cash flow used in operating activities	(3,15,27,949)	1,07,61,763
B Cash flows from investing activities		
Purchase of fixed assets	(5,25,43,018)	(3,23,43,332)
Net cash flows used in investing activities	(5,25,43,018)	(3,23,43,332)
C Cash flows from financing activities		
Proceeds from borrowings	8,26,05,745	2,33,26,884
	8,26,05,745	2,33,26,884
Net (decrease)/increase in cash and cash equivalents	(14,65,222)	17,45,315
Cash and cash equivalents at beginning of the year	39,22,536	21,77,221
Cash and cash equivalents at end of the year	24,57,314	39,22,536
Components of cash and cash equivalents		
Cash on hand	32,385	41,485
Balances with banks:		
in current accounts	24,24,929	38,81,051
Total cash and cash equivalents (also refer note 12)	24,57,314	39,22,536

Summary of significant accounting policies

2

Notes to and forming part of financial statements

3 - 30

The notes referred to above form an integral part of the financial statements

For ANRK & Associates LLP
Chartered Accountants
Firm Registration Number: W-100001




Abhijit Jadhav
Partner
Membership Number: 135735
Place: Pune
Date: 30 September 2019
UDIN: 19135735AAAaku2913




For and on behalf of the Board of Directors of
BVG Life Sciences Limited



Hanmantrao Gaikwad
Director
DIN: 01597365
Place: Pune
Date: 30 September 2019




Umesh Mane
Director
DIN: 01597742
Place: Pune
Date: 30 September 2019

BVG Life Sciences Limited

Notes to the financial statements for the year ended 31 March 2019

1. Background

BVG Life Sciences Limited ('the Company') is a limited company registered under Companies Act, 2013 ('the Act') was incorporated on 3 July 2014. The registered office of the Company is located at Pune. The Company is engaged in business of trading of agricultural products, agricultural chemicals, tea products and agricultural produce.

2. Significant accounting policies

2.1 Basis of preparation of financial statements

The financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India (GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Act, read together with paragraph 7 of the Companies (Accounts) Rules 2014. The financial statements have been prepared on accrual basis. The financial statements are presented in Indian rupees.

The Company is a Small and Medium Sized Company ('SMC') as defined in the General Instructions in respect of Accounting Standards notified under the Act. Accordingly, the Company has complied with the Accounting Standards as applicable to a SMC. Further, the Company by virtue of being a SMC, requires to comply with the recognition and measurement principles prescribed by all accounting standards, but is given a relaxation in respect of certain disclosure related standards and certain disclosure requirements prescribed by other accounting standards.

2.2 Use of estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amount of assets, liabilities and the disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenue and expenditure during the reporting period. Actual results may differ from those estimates. Any difference between the actual results and estimates are recognised in the period in which the results are known/ materialize. Any revision to accounting estimates is recognised prospectively in the current and future periods.

2.3 Current-non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

- a) it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b) it is held primarily for the purpose of being traded;
- c) it is expected to be realized within 12 months after the reporting date; or
- d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include current portion of non-current financial assets. All other assets are classified as non-current.



BVG Life Sciences Limited

Notes to the financial statements for the period ended 31 March 2019

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

- a) it is expected to be settled in the Company's normal operating cycle;
- b) it is held primarily for the purpose of being traded;
- c) it is expected to be settled within 12 months after the reporting date; or
- d) The Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include current portion of non-current financial liabilities. All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. The operating cycle of the Company is less than 12 months.

2.4 Revenue recognition

Sale of goods

Revenue from sale of goods is recognised when all significant risks and rewards of ownership of goods are passed onto the customers. The amount of revenue recognised is exclusive of Goods and Service Tax, discounts and rebates.

2.5 Accounting for taxes on income

Income tax

Income-tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income-tax law) and deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period). Income-tax expense is recognized in the Statement of Profit and Loss. Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the applicable tax rates and tax laws.

2.6 Earnings per equity share ('EPS')

The basic earnings/(loss) per share is computed by dividing the net profit/(loss) attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

2.7 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

2.8 Provisions and contingencies

A provision is recognised, if as a result of past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to



BVG Life Sciences Limited

Notes to the financial statements for the year ended 31 March 2019

settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the obligation at the Balance Sheet date. The provisions are measured on an undiscounted basis.

Contingencies

Provision in respect of loss contingencies relating to claims, litigations assessment, fines, penalties etc are recognised when it is probable that a liability has been incurred and the amount can be estimated reliably.

2.9 Contingent liabilities and contingent assets

A contingent liability exists when there is a possible but no obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognised nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefit will arise, the asset and related income are recognised in the period in which the change occurs.

2.10 Fixed assets and depreciation

Fixed assets are carried at acquisition cost less accumulated depreciation and/or impairment loss if any. The cost of an item comprises its purchase price including inward freight, duties, taxes, relevant foreign exchange fluctuation differences and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discounts and rebates are deducted in arriving at the purchase price.

Depreciation is provided on its useful life of the asset based on straight line method, in accordance with the provisions of the Act at the rates and in the manner specified in Schedule II.

2.11 Inventories

Inventories are stated at the lower of cost or net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and other costs necessary to make the sale. Cost is determined on the basis of first-in first-out (FIFO) method and includes expenditure in acquiring the inventories and other costs for bringing them to the present location and condition.

2.12 Foreign exchange transactions

Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the respective transaction. Exchange differences arising on the foreign currency transactions settled during the year are recognised in the Statement of Profit and Loss of the year. Monetary assets and liabilities denominated in foreign currency are translated at the year end exchange rate and the resultant exchange differences are recognised in the Statement of Profit and Loss of the year.



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

	31 March 2019	31 March 2018
3 Share capital		
Authorised capital		
50,000 (2018: 50,000) equity shares of Rs.10 each	5,00,000	5,00,000
	<u>5,00,000</u>	<u>5,00,000</u>
Issued, subscribed and paid up capital		
50,000 (2018: 50,000) equity shares of Rs.10 each	5,00,000	5,00,000
	<u>5,00,000</u>	<u>5,00,000</u>

Reconciliation of the number of shares and amount outstanding at the end of reporting date

	31 March 2019		31 March 2018	
	Numbers	Amount	Numbers	Amount
Equity shares				
At the commencement of the year	50,000	5,00,000	50,000	5,00,000
Add: Issued during the year	-	-	-	-
Outstanding at the end of the year	<u>50,000</u>	<u>5,00,000</u>	<u>50,000</u>	<u>5,00,000</u>

3.1 Rights, preferences and restrictions attached to equity shares

Equity shares

The Company has a single class of equity shares having a par value of Rs 10/- each. All equity shares shall be of the same class and shall be alike in all respects and the holders thereof shall be entitled to identical rights and privileges including without limitation to identical rights and privileges with respect to dividends, voting rights, and distribution of assets in the event of voluntary or involuntary liquidation, dissolution or winding up of the Company.

3.2 Shareholders holding more than 5 % shares of a class of shares

Name of the shareholders	31 March 2019		31 March 2018	
	Numbers of shares	% of holding	Numbers of shares	% of holding
Hanmantrao Gaikwad	19,000	38.00%	24,000	48.00%
Vaishali Gaikwad	18,100	36.20%	20,600	41.20%
Umesh Mane	5,000	10.00%	5,000	10.00%



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

	31 March 2019	31 March 2018
4 Reserves and surplus		
Balance in Statement of Profit and Loss		
Balance as per last Balance Sheet	9,00,282	(2,34,07,310)
Add: Profit for the year	88,91,894	16,58,739
Add: Prior period capitalisation	-	2,26,48,852
At the end of the year	<u>97,92,176</u>	<u>9,00,282</u>
5 Long term borrowings		
Unsecured loans		
From directors	15,27,37,384	11,33,37,384
From others	4,82,77,722	50,71,977
	<u>20,10,15,106</u>	<u>11,84,09,361</u>
Unsecured term loan from directors and others are interest free and repayable after 12 months after the Balance Sheet date, pursuant to agreement entered into by the Company.		
6 Trade payables		
Due to micro and small enterprises	-	-
Due to others	3,73,23,880	86,25,007
	<u>3,73,23,880</u>	<u>86,25,007</u>
7 Other current liabilities		
Statutory dues payable		
Value Added Tax	1,30,624	1,30,624
Tax deducted at source	7,82,068	3,48,359
GST Payable	-	17,93,461
Employee related liabilities	66,29,564	8,39,454
Security deposits payable	53,31,877	29,15,377
Provision for income tax	15,885	3,12,137
	<u>1,28,90,018</u>	<u>63,39,412</u>
9 Long-term loans and advances <i>(Unsecured, considered good unless stated otherwise)</i>		
Capital advances	25,21,867	75,05,900
Security deposits	7,67,425	3,75,025
MAT credit entitlement	20,22,937	3,12,137
Balances with government authorities		
Goods and service tax	37,58,640	-
	<u>90,70,869</u>	<u>81,93,062</u>
10 Inventories <i>(Valued at lower of cost or net realisable value)</i>		
Raw material	35,63,228	2,44,200
Packing material	3,99,148	4,36,211
Traded goods	1,13,46,437	6,78,278
Finished goods	1,48,30,221	63,74,194
	<u>3,01,39,034</u>	<u>77,32,883</u>
11 Trade receivables <i>(Unsecured, considered good unless otherwise stated)</i>		
Outstanding for a period exceeding six months from the date they become due for payment	-	-
Other receivables	7,06,94,287	2,19,81,347
	<u>7,06,94,287</u>	<u>2,19,81,347</u>
12 Cash and bank balances		
Cash and cash equivalents		
Cash on hand	32,385	41,485
Balances with bank		
in current accounts	24,24,929	38,81,051
	<u>24,57,314</u>	<u>39,22,536</u>
13 Short-term loans and advances		
Advance for supply of goods and services	4,21,93,237	3,79,55,493
Advances against salaries and wages	87,743	26,500
	<u>4,22,80,980</u>	<u>3,79,81,993</u>



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

8 (a) Tangible fixed assets (Property, plant and equipments)


Particulars	Leasehold Land	Plant and equipments	Office equipments	Furniture and fixtures	Vehicles	Computers	Total
Gross block							
Balance as at 1 April 2017	-	28,565	15,841	-	-	2,21,675	2,66,081
Additions	-	-	-	-	-	12,52,712	12,52,712
Disposals	-	-	-	-	-	-	-
Balance as at 31 March 2018		28,565	15,841	-	-	14,74,387	15,18,793
Balance as at 1 April 2018	-	28,565	15,841	-	-	14,74,387	15,18,793
Additions	1,19,24,614	22,38,825	1,09,003	30,616	66,423	1,89,980	1,45,59,461
Disposals	-	-	-	-	-	-	-
Balance as at 31 March 2019	1,19,24,614	22,67,390	1,24,844	30,616	66,423	16,64,367	1,60,78,254
Accumulated depreciation							
Balance as at 1 April 2017	-	1,426	1,480	-	-	17,749	20,655
Depreciation for the year	-	1,809	3,010	-	-	2,13,443	2,18,262
Depreciation on disposals	-	-	-	-	-	-	-
Balance as at 31 March 2018		3,235	4,490	-	-	2,31,191	2,38,916
Balance as at 1 April 2018	-	3,235	4,490	-	-	2,31,191	2,38,916
Depreciation for the year	-	46,163	11,247	741	3,734	4,83,211	5,45,096
Depreciation on disposals	-	-	-	-	-	-	-
Balance as at 31 March 2019		49,398	15,737	741	3,734	7,14,402	7,84,012
Net block							
Balance as at 31 March 2019	1,19,24,614	22,17,992	1,09,108	29,875	62,689	9,49,965	1,52,94,242
Balance as at 31 March 2018	-	25,330	11,351	-	-	12,43,196	12,79,877

8 (b) Intangible Assets

Particulars	Software	Total
Balance as at 1 April 2017	-	-
Additions	4,00,000	4,00,000
Disposals	-	-
Balance as at 31 March 2018	4,00,000	4,00,000
Balance as at 1 April 2018	4,00,000	4,00,000
Additions	3,27,000	3,27,000
Disposals	-	-
Balance as at 31 March 2019	7,27,000	7,27,000
Accumulated depreciation		
Balance as at 1 April 2017	-	-
Depreciation for the year	57,108	57,108
Depreciation on disposals	-	-
Balance as at 31 March 2018	57,108	57,108
Balance as at 1 April 2018	57,108	57,108
Depreciation for the year	81,467	81,467
Depreciation on disposals	-	-
Balance as at 31 March 2019	1,38,575	1,38,575
Net block		
Balance as at 31 March 2019	5,88,425	5,88,425
Balance as at 31 March 2018	3,42,892	3,42,892

8 (c) Capital work in progress - Product under development

Balance as at 1 April 2017	-
Additions	5,33,39,472
Capitalised during the year	-
Balance as at 31 March 2018	5,33,39,472
Balance as at 1 April 2018	5,33,39,472
Additions	3,76,56,557
Capitalised during the year	-
Balance as at 31 March 2019	9,09,96,029



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

	31 March 2019	31 March 2018
14 Revenue from operations		
Sale of products	17,81,61,424	5,65,89,435
Sale of services	1,46,41,014	-
	<u>19,28,02,438</u>	<u>5,65,89,435</u>
Breakup of revenue from sale of products		
Agricultural Products	11,53,76,686	4,27,67,928
Agricultural Produce	6,27,84,738	1,30,93,260
Others	-	7,28,247
	<u>17,81,61,424</u>	<u>5,65,89,435</u>
15 Other income		
Duty Drawback received	68,053	9,976
Sundry balances written back	-	2,093
Sale of MEIS duty scripts	16,19,831	-
Discounts received	2,16,369	-
Other income	3,63,806	-
	<u>22,68,059</u>	<u>12,069</u>
16 Cost of material consumed		
Raw material consumed		
Opening inventory	2,44,200	33,40,040
Add: Purchases	89,08,071	25,95,365
Less: Inventory at the end of the year	<u>35,63,228</u>	<u>2,44,200</u>
Cost of raw material consumed during the year	<u>55,89,043</u>	<u>56,91,205</u>
Packing material consumed		
Opening inventory	4,36,211	3,97,685
Add: Purchases	1,01,71,165	15,41,131
Less: Inventory at the end of the year	<u>3,99,148</u>	<u>4,36,211</u>
Cost of packing material consumed during the year	<u>1,02,08,228</u>	<u>15,02,605</u>
Total	<u>1,57,97,271</u>	<u>71,93,810</u>
17 Purchase of traded goods		
Purchases of traded goods	11,34,64,368	1,44,05,122
	<u>11,34,64,368</u>	<u>1,44,05,122</u>
Breakup of purchase of traded goods		
Agricultural Products	8,35,76,236	60,21,542
Agricultural Produce	2,98,88,132	75,68,413
Others	-	8,15,168
	<u>11,34,64,368</u>	<u>1,44,05,122</u>
18 (Increase)/Decrease in inventory of traded goods		
Inventory at the beginning of the year	70,52,472	2,35,86,029
Inventory at the end of the year	2,61,76,658	70,52,472
	<u>(1,91,24,186)</u>	<u>1,65,33,557</u>
Break-up of inventory of traded goods at the end of the year		
Traded goods	71,21,400	6,78,278
Finished goods	1,90,55,258	63,74,194
	<u>2,61,76,658</u>	<u>70,52,472</u>
19 Employee benefits		
Salary, wages and bonus	2,53,45,929	29,55,593
Contribution to provident and other funds	34,19,623	2,36,573
Staff welfare	13,98,766	1,34,414
	<u>3,01,64,318</u>	<u>33,26,580</u>
20 Other expenses		
Rent, rates and taxes	39,55,626	21,31,923
Freight and transportation charges	1,09,29,181	10,20,996
Repairs and maintenance	2,08,442	-
Labour charges	9,92,446	4,21,160
Consumption of stores and spares	26,00,460	83,564
Travelling and conveyance	1,16,03,533	34,58,494
Advertisement and business promotion expenses	35,99,702	14,57,721
Bank Charges	1,66,639	-
Communication expenses	6,88,803	1,41,597
Legal and professional fees	50,99,849	37,38,647
Payment to Auditors (Refer note 22)	1,33,080	1,72,895
Printing and stationery	6,92,189	1,95,335
Foreign exchange fluctuation loss	43,476	52,055
Sundry balances written off	18,87,924	-
Clearing & Forwarding Agent Charges	16,74,275	-
Bad debts written off	1,47,731	-
Miscellaneous expenses	8,26,913	3,33,940
	<u>4,52,50,269</u>	<u>1,32,08,325</u>



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

20 Related party transactions

A. Individuals having control over the Company (Key Managerial Personnel)

Hanmantrao Gaikwad	Director
Vaishali Gaikwad	Director (till 1 March 2019)
Umesh Mane	Director
Ganesh Limaye	Director (w.e.f. 1 March 2019)

B. Enterprises over which the Company or key management personnel or their relatives exercise significant influence:

BVG India Limited
 Livestock and Crop Registry India Limited
 Satara Mega Food Park Private Limited
 Yuvan Long Life Private Limited

C. Related party transactions carried out during the year ended March 2019

Sr. No.	Nature of transaction/ parties	31 March 2019		31 March 2018	
		Value of transactions	Balance Receivable/ (Payable)	Value of transactions	Balance Receivable/ (Payable)
1	BVG India Limited				
	Rent	10,20,030	-	26,28,280	(39,79,524)
	House Keeping Charges	4,08,000	-	-	-
	Manpower Supply Services	26,219	-	-	-
	Rates and taxes	2,99,442	-	-	-
	Marketing expenses	6,20,850	-	-	-
	Purchases	65,02,437	(57,63,720)	-	-
	Trade payable	-	(92,79,774)	-	-
	Sales	7,88,953	12,76,981	-	-
2	Hanmantrao Gaikwad				
	Loan received	4,00,10,000	(13,27,37,384)	6,27,02,644	(9,33,37,384)
	Loan Repaid	6,10,000	-	5,00,000	-
3	Vaishali Gaikwad				
	Remuneration	27,50,000	(2,02,891)	30,00,000	(2,04,554)
	Loan received	-	(2,00,00,000)	-	(2,00,00,000)
4	Satara Mega Food Park Private Limited				
	Advance for property on lease	80,00,000	-	-	50,00,000
	Purchase of open plot	1,11,74,614	-	-	-
	Rent	7,88,614	-	33,230	-
	Purchases	12,92,411	-	-	-
	Trade payable	-	(4,37,648)	-	(33,230)
5	Livestock and Crop Registry India Limited				
	Refund of advance	-	-	10,000	-
6	Yuvan Long Life Private Limited				
	Capital advances	15,967	10,21,867	5,900	10,05,900



BVG Life Sciences Limited

Notes to the financial statements for the financial year ended 31 March 2019 (continued)

31 March 2019 31 March 2018

21 Auditors' remuneration (on accrual basis, excluding taxes)

Statutory audit fees	1,00,000	1,00,000
Other matters	33,080	72,895
	1,33,080	1,72,895

22 Contingent liabilities and capital commitments: Nil (2018: Nil)

23 C.I.F. Value of imports: Nil (2018: Nil)

24 Expenditure in foreign currency (accrual basis): Nil (2018: Nil)

25 Earnings in foreign currency:

Sale of Grapes	22,46,088	46,84,599
Sale of Pomegranate	3,67,51,298	84,08,661
Sale of Onion	2,04,33,354	-
Sale of other agricultural products	21,28,400	-
	6,15,59,140	1,30,93,260

26 Foreign currency exposures outstanding at the year end

The following foreign currency receivables/payables balances are not covered by derivative instruments at the Balance Sheet date:

Particulars	Amount in foreign currency		Equivalent amount in Rs.	
	31 March 2019	31 March 2018	31 March 2019	31 March 2018
Trade receivables (Currency: AED)	5,97,888	22,196	1,12,93,680	3,93,280
Trade receivables (Currency: LKR)	40,89,257	1,10,72,724	16,18,528	46,29,506

27 Micro, Small and Medium Enterprises Development Act, 2006

The Company has not received any intimation from its suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosures, if any relating to amounts unpaid as at the period end together with interest paid / payable as required under the Act are not applicable. (2018: Nil)

28 Earnings per share

Net profit for the year attributable to equity shareholders	A	88,91,894	16,58,740
Weighted average number of equity shares of face value of Rs. 10 each outstanding during the year	B	50,000	50,000
Basic and diluted earnings per equity share of Rs. 10 each	(A/B)	177.84	33.17


29 Derivative instruments

The Company does not have any derivative instruments outstanding at the Balance Sheet date.

30 Lease

The Company has entered into operating lease arrangements for office premises and plant and equipments. The lease arrangement provide for cancellation by either party and also contain a clause for renewal of the lease agreement. Lease payments on cancellable operating lease arrangements debited to the Statement of Profit and Loss amount to Rs. 30,62,960 (2018: Rs. 14,31,923)


For ANRK & Associates LLP
Chartered Accountants
Firm Registration Number: W-100001




Abhijit Jadhav
Partner
Membership Number: 135735
Place: Pune
Date: 30 September 2019
UDIN: 19135735AAAKU2913



For and on behalf of the Board of Directors of
BVG Life Sciences Limited



Hanmantao Gaikwad
Director
DIN: 01597365
Place: Pune
Date: 30 September 2019




Umesh Mane
Director
DIN: 01597742
Place: Pune
Date: 30 September 2019